1. Home
  2. GXO vs RYTM Comparison

GXO vs RYTM Comparison

Compare GXO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GXO Logistics Inc.

GXO

GXO Logistics Inc.

HOLD

Current Price

$58.65

Market Cap

6.6B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$84.74

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXO
RYTM
Founded
2021
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.9B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
GXO
RYTM
Price
$58.65
$84.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
14
Target Price
$67.91
$131.14
AVG Volume (30 Days)
1.0M
778.7K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
0.28
N/A
Revenue
$13,178,000,000.00
N/A
Revenue This Year
$6.81
$55.34
Revenue Next Year
$5.95
$86.06
P/E Ratio
$211.21
N/A
Revenue Growth
12.55
N/A
52 Week Low
$34.80
$55.31
52 Week High
$66.85
$122.20

Technical Indicators

Market Signals
Indicator
GXO
RYTM
Relative Strength Index (RSI) 61.73 44.88
Support Level $51.93 $82.98
Resistance Level $66.85 $100.70
Average True Range (ATR) 1.75 3.50
MACD 0.77 0.59
Stochastic Oscillator 82.41 25.91

Price Performance

Historical Comparison
GXO
RYTM

About GXO GXO Logistics Inc.

GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: